pGL4.31[luc2P/Gal4UAS/Hygro] Vector
Study Mammalian Protein Interactions, Expression and Post-Translational Modifications
- Confirm, validate and study suspected protein or domain interactions
- Generate stable cell lines for cell-based assays
- Enables mammalian protein expression and post-translational modification studies in situ
Catalog Number:
Size
Catalog Number: C9351
オリジナルのCheckMate™ Mammalian Two-Hybrid Systemから進化した新しいフレキシブルクローニングシステムに追加された機能として大きく2つの点が挙げられます。クローニングの容易なフレキシブルクローニングシステムを採用しており、他の機能を有するFlexi® Vectorへのダイレクショナルクローニングが迅速、簡単に行える。 レポーターベクター のルシフェラーゼ遺伝子がS/N比の高い改良型luc2になり、分解配列も付加されているため、応答に優れた実験が可能となり、さらにハイグロマイシン耐性遺伝子も付加されて、安定株の作成を容易にします。
- 哺乳動物システム：目的に合った哺乳細胞株で相互作用実験が行えるため、タンパク質はよりネイティブに近い状態になります（グリコシレーション、リン酸化、アシル化などの翻訳後修飾を受けやすい）。
- 柔軟性：他のタンパク質解析機能を持つFlexi®ベクターへのタンパク質コード領域の移し変えが容易なフレキシクローニングシステムと従来的なクローニングが行えるオリジナルベクターシステム
- 便利：デュアル－ルシフェラーゼアッセイなど各種ルシフェラーゼ定量試薬から目的に応じたシステムを選択できます。長時間発光タイプを用いれば、タンパク質相互作用のハイスループットスクリーニングが行えます。
- 短期間で解析：トランスフェクション後約2日で結果が得られます（酵母のシステムは3-4日）
- ステイブル：ACTベクターはネオマイシン耐性遺伝子、pGL4.31ベクターはハイグロマイシン耐性遺
- 期待されるタンパク質間相互作用の確認や相互作用ドメインの同定
- スクリーニング
For more information, see the Protocols & Applications Guide.
【ライセンス】pGL4ベクターシリーズ
Protocols
Complete Protocol
Specifications
Catalog Number:
選択製品の構成品内容
| Item | Part # | Size | Available Separately |
|---|---|---|---|
pGL4.31[luc2P/Gal4UAS/Hygro] Vector |
C935A | 1 × 20μg | View Product |
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE LABEL LICENSE. If the researcher is not willing to accept the terms of this label license, and the product is unused, Promega will accept return of the unused product and provide the researcher with a full refund.
Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for money or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research. Researchers shall have no right to modify or otherwise create variations of the nucleotide sequence of the luciferase gene except that researchers may: (1) create fused gene sequences provided that the coding sequence of the resulting luciferase gene has no more than four deoxynucleotides missing at the affected terminus compared to the intact luciferase gene sequence, and (2) insert and remove nucleic acid sequences in splicing research predicated on the inactivation or reconstitution of the luminescence of the encoded luciferase. No other use or transfer of this product or derivatives is authorized without the prior express written consent of Promega. In addition, researchers must either: (1) use luminescent assay reagents purchased from Promega for all determinations of luminescence activity of this product and its derivatives; or (2) contact Promega to obtain a license for use of the product and its derivatives. Researchers may transfer derivatives to others for research use provided that at the time of transfer a copy of this label license is given to the recipients and recipients agree to be bound by the terms of this label license. With respect to any uses outside this label license, including any diagnostic, therapeutic or prophylactic uses, please contact Promega for supply and licensing information. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING FOR MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THE PRODUCT. The terms of this label license shall be governed under the laws of the State of Wisconsin, USA.
U.S. Pat. No. 7,728,118.
